Perifosine: Final Phase II data
Final data from a Phase II trial in 40 patients with relapsed and/or refractory lymphomas who failed second- or subsequent-line salvage chemotherapy showed that patients who achieved less than a partial response after 4 weeks of treatment with 50 mg twice-daily perifosine (n=36), perifosine plus twice-daily 400 mg sorafenib produced 8 partial responses and 15 cases of stable disease. Median time to achieve a partial response and median duration of response were both 4 months. Median OS was 16 months and median PFS was 5 months. In a subgroup of 25 patients with Hodgkin's lymphoma, perifosine plus sorafenib produced 7 partial responses. The combination was well tolerated. Data were presented at the American Society of Hematology meeting in Atlanta. ...